Timo Vesikari

20.2k total citations · 3 hit papers
272 papers, 12.3k citations indexed

About

Timo Vesikari is a scholar working on Infectious Diseases, Cardiology and Cardiovascular Medicine and Epidemiology. According to data from OpenAlex, Timo Vesikari has authored 272 papers receiving a total of 12.3k indexed citations (citations by other indexed papers that have themselves been cited), including 197 papers in Infectious Diseases, 102 papers in Cardiology and Cardiovascular Medicine and 83 papers in Epidemiology. Recurrent topics in Timo Vesikari's work include Viral gastroenteritis research and epidemiology (184 papers), Viral Infections and Immunology Research (102 papers) and Animal Virus Infections Studies (78 papers). Timo Vesikari is often cited by papers focused on Viral gastroenteritis research and epidemiology (184 papers), Viral Infections and Immunology Research (102 papers) and Animal Virus Infections Studies (78 papers). Timo Vesikari collaborates with scholars based in Finland, United States and Belgium. Timo Vesikari's co-authors include Tarja Ruuska, Aino Karvonen, Erika Isolauri, Vesna Blazevic, A. Delem, Suvi Lappalainen, Jaana Joensuu, Leena Huhti, Xiaoli Pang and Marjo Salminen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and PLoS ONE.

In The Last Decade

Timo Vesikari

268 papers receiving 11.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Live Attenuated versus Inactivated Influenza Vaccine in Infants and Young Children

2007 611 citations Timo Vesikari et al. profile →
Rotavirus Disease in Finnish Children: Use of Numerical Scores for Clinical Severity of Diarrhoeal Episodes

1990 589 citations Timo Vesikari et al. profile →
Efficacy of human rotavirus vaccine against rotavirus gastroenteritis during the first 2 years of life in European infants: randomised, double-blind controlled study

2007 510 citations Timo Vesikari, Aino Karvonen et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Timo Vesikari	8.3k	4.0k	3.9k	2.7k	2.5k	272	12.3k
Robert L. Atmar	12.9k 1.5×	5.3k 1.3×	3.7k 1.0×	4.3k 1.6×	1.7k 0.7×	270	19.4k
Albert Z. Kapikian	13.5k 1.6×	4.3k 1.1×	4.6k 1.2×	5.5k 2.1×	3.2k 1.3×	223	16.8k
A. Duncan Steele	10.7k 1.3×	779 0.2×	5.9k 1.5×	3.5k 1.3×	4.8k 1.9×	276	12.0k
Hubert G.M. Niesters	4.9k 0.6×	8.5k 2.1×	1.5k 0.4×	962 0.4×	4.1k 1.6×	304	14.3k
M. Steven Oberste	9.7k 1.2×	5.1k 1.3×	10.5k 2.7×	1.6k 0.6×	261 0.1×	230	14.3k
Jacqueline E. Tate	9.9k 1.2×	1.1k 0.3×	4.6k 1.2×	3.0k 1.1×	4.5k 1.8×	285	11.1k
Baoming Jiang	6.6k 0.8×	662 0.2×	3.5k 0.9×	2.7k 1.0×	2.2k 0.9×	172	7.5k
Harry Vennema	10.5k 1.3×	2.0k 0.5×	3.0k 0.8×	4.5k 1.7×	2.2k 0.9×	159	12.2k
Carl D. Kirkwood	6.8k 0.8×	901 0.2×	3.8k 1.0×	2.9k 1.1×	2.0k 0.8×	173	8.1k
Neil R. Blacklow	5.0k 0.6×	1.6k 0.4×	1.2k 0.3×	1.7k 0.6×	824 0.3×	112	8.0k

Countries citing papers authored by Timo Vesikari

Since Specialization

Citations

This map shows the geographic impact of Timo Vesikari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timo Vesikari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timo Vesikari more than expected).

Fields of papers citing papers by Timo Vesikari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timo Vesikari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timo Vesikari. The network helps show where Timo Vesikari may publish in the future.

Co-authorship network of co-authors of Timo Vesikari

This figure shows the co-authorship network connecting the top 25 collaborators of Timo Vesikari. A scholar is included among the top collaborators of Timo Vesikari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timo Vesikari. Timo Vesikari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Vesikari, Timo, et al.. (2023). PreHevbrio: the first approved 3-antigen hepatitis B vaccine. Expert Review of Vaccines. 22(1). 1041–1054. 9 indexed citations

Paloniemi, Minna, Timo Vesikari, Maija Lappalainen, et al.. (2021). Human Protoparvovirus DNA and IgG in Children and Adults with and without Respiratory or Gastrointestinal Infections. Viruses. 13(3). 483–483. 13 indexed citations

Tamminen, Kirsi, et al.. (2020). Rotavirus VP6 Adjuvant Effect on Norovirus GII.4 Virus‐Like Particle Uptake and Presentation by Bone Marrow‐Derived Dendritic Cells In Vitro and In Vivo. Journal of Immunology Research. 2020(1). 3194704–3194704. 11 indexed citations

Martinón‐Torres, Federico, Xavier Bosch, Rino Rappuoli, et al.. (2019). TIPICO IX: report of the 9^th interactive infectious disease workshop on infectious diseases and vaccines. Human Vaccines & Immunotherapeutics. 15(10). 2405–2415. 20 indexed citations

Malm, Maria, Kirsi Tamminen, Suvi Lappalainen, Timo Vesikari, & Vesna Blazevic. (2016). Rotavirus Recombinant VP6 Nanotubes Act as an Immunomodulator and Delivery Vehicle for Norovirus Virus-Like Particles. Journal of Immunology Research. 2016. 1–13. 29 indexed citations

Tamminen, Kirsi, Maria Malm, Timo Vesikari, & Vesna Blazevic. (2016). Mucosal Antibodies Induced by Intranasal but Not Intramuscular Immunization Block Norovirus GII.4 Virus-Like Particle Receptor Binding. Viral Immunology. 29(5). 315–319. 16 indexed citations

Lappalainen, Suvi, Vesna Blazevic, Maria Malm, & Timo Vesikari. (2016). Rotavirus vaccination and infection induce VP6‐specific IgA responses. Journal of Medical Virology. 89(2). 239–245. 9 indexed citations

Vesikari, Timo, Jan Hendrik Richardus, Johan Berglund, et al.. (2015). Immunogenicity and Safety of a Trivalent Inactivated Influenza Vaccine in Children 6 Months to 17 Years of Age, Previously Vaccinated with an AS03-Adjuvanted A(H1N1)Pdm09 Vaccine. The Pediatric Infectious Disease Journal. 34(7). 774–782. 5 indexed citations

Hemming, Maria, et al.. (2014). Detection of Vaccine-derived Rotavirus Strains in Nonimmunocompromised Children up to 3–6 Months After RotaTeq® Vaccination. The Pediatric Infectious Disease Journal. 34(3). 296–298. 21 indexed citations

10.

Uusi-Kerttula, Hanni, Kirsi Tamminen, Maria Malm, Timo Vesikari, & Vesna Blazevic. (2014). Comparison of human saliva and synthetic histo-blood group antigens usage as ligands in norovirus-like particle binding and blocking assays. Microbes and Infection. 16(6). 472–480. 33 indexed citations

11.

Tamminen, Kirsi, Leena Huhti, Timo Vesikari, & Vesna Blazevic. (2013). Pre-existing Immunity to Norovirus GII-4 Virus-Like Particles Does Not Impair de Novo Immune Responses to Norovirus GII-12 Genotype. Viral Immunology. 26(2). 167–170. 10 indexed citations

12.

Puustinen, Leena, Vesna Blazevic, Leena Huhti, et al.. (2011). Norovirus genotypes in endemic acute gastroenteritis of infants and children in Finland between 1994 and 2007. Epidemiology and Infection. 140(2). 268–275. 43 indexed citations

13.

Vesikari, Timo. (2008). Serotype-Specific Efficacy of the Pentavalent Rotavirus Vaccine against Hospitalizations and Emergency Department Visits up to Three Years: The Finnish Extension Study. 46th Annual Meeting. 2 indexed citations

14.

Vesikari, Timo, et al.. (2008). Efficacy of Pentavalent Rotavirus Vaccine, RotaTeq™, against Hospitalizations and Emergency Department Visits through the Third Year: The Finnish Extension Study. International Journal of Infectious Diseases. 12. e149–e149. 2 indexed citations

15.

Vesikari, Timo. (2007). RIX4414 ( Rotarix ™) is Highly Effective against Severe RVGE Caused by Specific Rotavirus Types during the First Two Years of Life.. 1 indexed citations

16.

Krohn, Kai, et al.. (2005). A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A–C subtypes and the ancestor sequence of the F–H subtypes. Preclinical and clinical studies. Microbes and Infection. 7(14). 1405–1413. 22 indexed citations

17.

Pang, Xiaoli, Shang‐Qin Zeng, Shinjiro Honma, Shuji Nakata, & Timo Vesikari. (2001). Effect of rotavirus vaccine on Sapporo virus gastroenteritis in Finnish infants. The Pediatric Infectious Disease Journal. 20(3). 295–300. 15 indexed citations

18.

Vesikari, Timo, et al.. (1988). Neurologic Sequelae Following Interferon Therapy of Juvenile Laryngeal Papilloma. Acta Paediatrica. 77(4). 619–622. 30 indexed citations

19.

Vesikari, Timo, Erika Isolauri, A. Delem, et al.. (1985). Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic. The Journal of Pediatrics. 107(2). 189–194. 135 indexed citations

20.

Vesikari, Timo, Kaisa Granfors, Markku Mäki, & P Grönroos. (1980). Evaluation of ELISA in the diagnosis of Yersinia enterocolitica diarrhoea in children.. Apmis. 139–142. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact